Histogenics and FDA Conclude Discussions Regarding NeoCart Phase 3 Clinical Trial Data and Regulatory Pathway
Histogenics and FDA Continue to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart in Patients With Knee Cartilage Damage
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
